DexCom, Inc. — Q1 2014 Form 10-Q
Business context and period: Medical-device company focused on continuous glucose monitoring (CGM) systems. This unaudited filing covers the three months ended March 31, 2014; comparisons are with Q1 2013 unless otherwise noted. Dollar amounts are in millions except per-share data.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Product revenue | $46.7 | $27.8 |
| Development grant and other revenue | $0.4 | $1.8 |
| Total revenue | $47.1 | $29.6 |
| Gross profit | $29.8 | $16.5 |
| Gross margin | 63.3% | 55.7% |
| Operating expenses | $42.1 | $27.4 |
| Operating loss | $(12.3) | $(10.9) |
| Net loss | $(12.5) | $(11.1) |
| Basic and diluted loss per share | $(0.17) | $(0.16) |
| Cash used in operating activities | $(2.4) | $(4.5) |
Balance sheet and funding: At March 31, cash, cash equivalents and short-term marketable securities totaled $57.4, excluding $1.0 of restricted cash; working capital was $63.9. Total debt was $6.3 ($2.2 current and $4.1 long term). The $15.0 revolving credit line was undrawn. Cash and cash equivalents rose to $45.7 from $43.2 at year-end. Q1 investing cash outflow was $4.3, including $3.9 for property and equipment; financing provided $9.2, including $9.7 of net proceeds from common-stock issuance and $0.5 of debt repayment.
Material changes versus Q1 2013
- Total revenue increased 59%, mainly on higher durable-system and sensor sales following the G4 PLATINUM launch and growth in the installed customer base. Product gross profit also benefited from a higher mix of G4 PLATINUM, which management described as higher-margin than SEVEN PLUS.
- Gross margin improved to 63.3% from 55.7%. Operating expenses rose $14.7, with R&D up $5.2 and SG&A up $9.5, reflecting added staffing, commercialization and infrastructure costs, clinical and development spending, and higher share-based compensation.
- Development and other revenue declined $1.4, primarily because Roche terminated its development agreement in February 2013. Total net loss widened by $1.4.
- Operating cash use decreased by $2.1, partly because of higher non-cash expenses, including share-based compensation; this improvement did not reflect a reduction in net loss.
Outlook, risks and unusual items
- Management expects continued net losses as it expands commercialization, R&D, manufacturing and infrastructure. It believes available resources and projected partnership contributions will fund anticipated requirements through at least March 31, 2015; this is not a profitability forecast.
- The company received FDA approval on February 3, 2014 for a pediatric indication for G4 PLATINUM. An FDA supplement for professional use and the DexCom SHARE remote-monitoring system remained under review in the periods described.
- Manufacturing capacity, product quality and supply, regulatory approvals, clinical development, third-party reimbursement, competition and the ability to achieve sufficient sales remain significant risks. Medicare had not adopted a national CGM coverage decision; private coverage was described as restrictive.
- Following a November 2013 FDA inspection and Form 483 observations concerning medical-device reporting procedures, DexCom received an FDA warning letter on March 14, 2014. It responded on April 2; the FDA was reviewing the response. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
- Abbott patent litigation remains unresolved, including a new infringement complaint and motions concerning consolidation and a stay. DexCom said it could not assess the outcome or potential costs and had accrued no amounts. Abbott also pursued patent reexaminations and European oppositions.
- SweetSpot contingent consideration was remeasured to $5.4, up from $4.2 at year-end; the $1.2 increase was recorded in operating expenses. Share-based compensation was $8.7 versus $5.0 a year earlier, with $140.0 of estimated unrecognized compensation cost expected to be recognized through 2018.
- Purchase commitments due within one year totaled $21.5. The Helmsley Trust grant provides up to $4.0 for Gen 6 Sensor development, subject to milestones; successful commercialization may trigger royalties or a one-time payment.
Important facts for investors to verify
- Whether sales and the improved gross margin persist as the G4 PLATINUM customer base grows, and whether operating-expense growth moderates.
- Whether reimbursement coverage expands and supports recurring sensor purchases, particularly given the absence of Medicare national coverage.
- Progress on manufacturing capacity, supply reliability and the FDA’s review of DexCom’s response to the warning letter.
- Developments and potential costs in the Abbott patent matters; no litigation accrual was recorded and the outcome was not estimable.
- Cash consumption, access to additional financing, debt-covenant compliance and the assumptions underlying management’s liquidity runway through March 31, 2015.